Plumericin inhibits proliferation of vascular smooth muscle cells by blocking STAT3 signaling via S-glutathionylation

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Heiss, Elke H ^a   Liu, Rongxia ^a,e   Waltenberger, Birgit ^b   Khan, Shafaat ^c,d   Schachner, Daniel ^a   Kollmann, Paul ^a   Zimmermann, Kristin ^a   Cabaravdic, Muris ^c   Uhrin, Pavel ^c   Stuppner, Hermann ^b   Breuss, Johannes M ^c   Atanasov, Atanas G ^a   Dirsch, Verena M ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF SARGODHA   (Pakistan)

^e YANTAI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CCND1 PROTEIN, RAT; CYCLIN D1; GLUTATHIONE; INDENE DERIVATIVE; IRIDOID; PLUMERICIN; STAT3 PROTEIN; STAT3 PROTEIN, RAT;

ANIMAL; APOCYNACEAE; BIOSYNTHESIS; CELL CULTURE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CHEMISTRY; DRUG EFFECTS; METABOLISM; PATHOLOGY; PROTEIN PROCESSING; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CELL; VASCULAR SMOOTH MUSCLE;

ANIMALS; APOCYNACEAE; CELLS, CULTURED; CYCLIN D1; G1 PHASE; GLUTATHIONE; INDENES; IRIDOIDS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PROTEIN PROCESSING, POST-TRANSLATIONAL; RATS; RESTING PHASE, CELL CYCLE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84957581732     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep20771     Document Type: Article

References (67)

1. Lusis, A. J. Atherosclerosis. Nature 407, 233-241, doi: 10.1038/35025203 (2000).
2. Legein, B., Temmerman, L., Biessen, E. A. & Lutgens, E. Inflammation and immune system interactions in atherosclerosis. Cell Mol Life Sci 70, 3847-3869, doi: 10.1007/s00018-013-1289-1 (2013).
3. Hansson, G. K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352, 1685-1695, doi: 10.1056/NEJMra043430 (2005).
4. Libby, P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 32, 2045-2051, doi: 10.1161/ATVBAHA.108.179705 (2012).
5. Libby, P. Inflammation in atherosclerosis. Nature 420, 868-874, doi: 10.1038/nature01323 (2002).
6. Mills, B., Robb, T. & Larson, D. F. Intimal hyperplasia: slow but deadly. Perfusion 27, 520-528, doi: 10.1177/0267659112452316 (2012).
7. Thyberg, J., Hedin, U., Sjolund, M., Palmberg, L. & Bottger, B. A. Regulation of differentiated properties and proliferation of arterial smooth muscle cells. Arteriosclerosis 10, 966-990 (1990).
8. Braun-Dullaeus, R. C., Mann, M. J. & Dzau, V. J. Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation 98, 82-89 (1998).
9. Kinghorn, A. D., Pan, L., Fletcher, J. N. & Chai, H. The relevance of higher plants in lead compound discovery programs. J Nat Prod 74, 1539-1555, doi: 10.1021/np200391c (2011).
10. Cragg, G. M. & Newman, D. J. Natural products: a continuing source of novel drug leads. Biochim Biophys Acta 1830, 3670-3695, doi: 10.1016/j.bbagen.2013.02.008 (2013).
11. Atanasov, A. G. et al. Discovery and resupply of pharmacologically active plant-derived natural products: A review. Biotechnol Adv, doi: 10.1016/j.biotechadv.2015.08.001 (2015).
12. Waltenberger, B., Rollinger, J. M., Griesser, U. J., Stuppner, H. & Gelbrich, T. Plumeridoid C from the Amazonian traditional medicinal plant Himatanthus sucuuba. Acta Crystallogr C 67, o409-412, doi: 10.1107/S0108270111035761 (2011).
13. Fakhrudin, N. et al. Identification of plumericin as a potent new inhibitor of the NF-kappaB pathway with anti-inflammatory activity in vitro and in vivo. Br J Pharmacol 171, 1676-1686, doi: 10.1111/bph.12558 (2014).
14. Perdue, G. P. & Blomster, R. N. South American plants III: Isolation of fulvoplumierin from Himatanthus sucuuba (M. Arg.) Woodson (Apocynaceae). J Pharm Sci 67, 1322-1323 (1978).
15. de Miranda, A. L. et al. Anti-inflammatory and analgesic activities of the latex containing triterpenes from Himatanthus sucuuba. Planta Med 66, 284-286, doi: 10.1055/s-2000-8572 (2000).
16. Wood, C. A. et al. A bioactive spirolactone iridoid and triterpenoids from Himatanthus sucuuba. Chem Pharm Bull (Tokyo) 49, 1477-1478 (2001).
17. Sharma, U., Singh, D., Kumar, P., Dobhal, M. P. & Singh, S. Antiparasitic activity of plumericin & isoplumericin isolated from Plumeria bicolor against Leishmania donovani. Indian J Med Res 134, 709-716, doi: 10.4103/0971-5916.91005 (2011).
18. Kuigoua, G. M. et al. Minor secondary metabolic products from the stem bark of Plumeria rubra Linn. displaying antimicrobial activities. Planta Med 76, 620-625, doi: 10.1055/s-0029-1240611 (2010).
19. Singh, D. et al. Antifungal activity of plumericin and isoplumericin. Nat Prod Commun 6, 1567-1568 (2011).
20. Sollott, S. J. et al. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J Clin Invest 95, 1869-1876, doi: 10.1172/JCI117867 (1995).
21. Kato, J. Induction of S phase by G1 regulatory factors. Front Biosci 4, D787-792 (1999).
22. Sherr, C. J. Cancer cell cycles. Science 274, 1672-1677 (1996).
23. Knudsen, E. S. & Wang, J. Y. Dual mechanisms for the inhibition of E2F binding to RB by cyclin-dependent kinase-mediated RB phosphorylation. Mol Cell Biol 17, 5771-5783 (1997).
24. Klein, E. A. & Assoian, R. K. Transcriptional regulation of the cyclin D1 gene at a glance. J Cell Sci 121, 3853-3857, doi: 10.1242/jcs.039131 (2008).
25. Mehrhof, F. B., Schmidt-Ullrich, R., Dietz, R. & Scheidereit, C. Regulation of vascular smooth muscle cell proliferation: role of NF-kappaB revisited. Circ Res 96, 958-964, doi: 10.1161/01.RES.0000166924.31219.49 (2005).
26. Schust, J., Sperl, B., Hollis, A., Mayer, T. U. & Berg, T. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol 13, 1235-1242, doi: 10.1016/j.chembiol.2006.09.018 (2006).
27. Zgheib, C. et al. Acyloxy nitroso compounds inhibit LIF signaling in endothelial cells and cardiac myocytes: evidence that STAT3 signaling is redox-sensitive. PLoS One 7, e43313, doi: 10.1371/journal.pone.0043313 (2012).
28. Sobotta, M. C. et al. Peroxiredoxin-2 and STAT3 form a redox relay for H2O2 signaling. Nat Chem Biol 11, 64-70, doi: 10.1038/nchembio.1695 (2015).
29. Li, L. & Shaw, P. E. A STAT3 dimer formed by inter-chain disulphide bridging during oxidative stress. Biochem Biophys Res Commun 322, 1005-1011, doi: 10.1016/j.bbrc.2004.08.014 (2004).
30. Butturini, E. et al. S-Glutathionylation at Cys328 and Cys542 impairs STAT3 phosphorylation. ACS Chem Biol 9, 1885-1893, doi: 10.1021/cb500407d (2014).
31. Xie, Y., Kole, S., Precht, P., Pazin, M. J. & Bernier, M. S-glutathionylation impairs signal transducer and activator of transcription 3 activation and signaling. Endocrinology 150, 1122-1131, doi: 10.1210/en.2008-1241 (2009).
32. Butturini, E. et al. Two naturally occurring terpenes, dehydrocostuslactone and costunolide, decrease intracellular GSH content and inhibit STAT3 activation. PLoS One 6, e20174, doi: 10.1371/journal.pone.0020174 (2011).
33. Ghezzi, P. & Di Simplicio, P. Glutathionylation pathways in drug response. Curr Opin Pharmacol 7, 398-403, doi: 10.1016/j.coph.2007.04.006 (2007).
34. Gallogly, M. M. & Mieyal, J. J. Mechanisms of reversible protein glutathionylation in redox signaling and oxidative stress. Curr Opin Pharmacol 7, 381-391, doi: 10.1016/j.coph.2007.06.003 (2007).
35. Winterbourn, C. C. & Hampton, M. B. Thiol chemistry and specificity in redox signaling. Free Radic Biol Med 45, 549-561, doi: 10.1016/j.freeradbiomed.2008.05.004 (2008).
36. Yu, C. L. et al. Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science 269, 81-83 (1995).
37. Liao, X. H. et al. STAT3 Protein Regulates Vascular Smooth Muscle Cell Phenotypic Switch by Interaction with Myocardin. J Biol Chem 290, 19641-19652, doi: 10.1074/jbc.M114.630111 (2015).
38. Sun, J. et al. Preventing intimal thickening of vein grafts in vein artery bypass using STAT-3 siRNA. J Transl Med 10, 2, doi: 10.1186/1479-5876-10-2 (2012).
39. Schwaiberger, A. V. et al. Indirubin-3′-monoxime blocks vascular smooth muscle cell proliferation by inhibition of signal transducer and activator of transcription 3 signaling and reduces neointima formation in vivo. Arterioscler Thromb Vasc Biol 30, 2475-2481, doi: 10.1161/ATVBAHA.110.212654 (2010).
40. Dutzmann, J., Daniel, J. M., Bauersachs, J., Hilfiker-Kleiner, D. & Sedding, D. G. Emerging translational approaches to target STAT3 signalling and its impact on vascular disease. Cardiovasc Res 106, 365-374, doi: 10.1093/cvr/cvv103 (2015).
41. Butturini, E. et al. Mild oxidative stress induces S-glutathionylation of STAT3 and enhances chemosensitivity of tumoural cells to chemotherapeutic drugs. Free Radic Biol Med 65, 1322-1330, doi: 10.1016/j.freeradbiomed.2013.09.015 (2013).
42. Baird, L. & Dinkova-Kostova, A. T. The cytoprotective role of the Keap1-Nrf2 pathway. Arch Toxicol 85, 241-272, doi: 10.1007/s00204-011-0674-5 (2011).
43. Moinova, H. R. & Mulcahy, R. T. Up-regulation of the human gamma-glutamylcysteine synthetase regulatory subunit gene involves binding of Nrf-2 to an electrophile responsive element. Biochem Biophys Res Commun 261, 661-668, doi: 10.1006/bbrc.1999.1109 (1999).
44. Liu, R. et al. Identification and characterization of [6]-shogaol from ginger as inhibitor of vascular smooth muscle cell proliferation. Mol Nutr Food Res 59, 843-852, doi: 10.1002/mnfr.201400791 (2015).
45. Heiss, E. H. et al. Identification of chromomoric acid C-I as an Nrf2 activator in Chromolaena odorata. J Nat Prod 77, 503-508, doi: 10.1021/np400778m (2014).
46. Kim, S. E. et al. Role of Pin1 in neointima formation: down-regulation of Nrf2-dependent heme oxygenase-1 expression by Pin1. Free Radic Biol Med 48, 1644-1653, doi: 10.1016/j.freeradbiomed.2010.03.013 (2010).
47. Heiss, E. H., Schachner, D., Werner, E. R. & Dirsch, V. M. Active NF-E2-related factor (Nrf2) contributes to keep endothelial NO synthase (eNOS) in the coupled state: role of reactive oxygen species (ROS), eNOS, and heme oxygenase (HO-1) levels. J Biol Chem 284, 31579-31586, doi: 10.1074/jbc.M109.009175 (2009).
48. Chen, X. L. et al. Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression. Am J Physiol Heart Circ Physiol 290, H1862-1870, doi: 10.1152/ajpheart.00651.2005 (2006).
49. Rodriguez, A. I. et al. HO-1 and CO decrease platelet-derived growth factor-induced vascular smooth muscle cell migration via inhibition of Nox1. Arterioscler Thromb Vasc Biol 30, 98-104, doi: 10.1161/ATVBAHA.109.197822 (2010).
50. Liu, Z. et al. Tanshinone IIA suppresses cholesterol accumulation in human macrophages: role of heme oxygenase-1. J Lipid Res 55, 201-213, doi: 10.1194/jlr.M040394 (2014).
51. Banning, A. & Brigelius-Flohe, R. NF-kappaB, Nrf2, and HO-1 interplay in redox-regulated VCAM-1 expression. Antioxid Redox Signal 7, 889-899, doi: 10.1089/ars.2005.7.889 (2005).
52. Fitzpatrick, L. R., Stonesifer, E., Small, J. S. & Liby, K. T. The synthetic triterpenoid (CDDO-Im) inhibits STAT3, as well as IL-17, and improves DSS-induced colitis in mice. Inflammopharmacology 22, 341-349, doi: 10.1007/s10787-014-0203-2 (2014).
53. Liby, K. et al. The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res 65, 4789-4798, doi: 10.1158/0008-5472.CAN-04-4539 (2005).
54. Yore, M. M., Liby, K. T., Honda, T., Gribble, G. W. & Sporn, M. B. The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-kappaB activation through direct inhibition of IkappaB kinase beta. Mol Cancer Ther 5, 3232-3239, doi: 10.1158/1535-7163.MCT-06-0444 (2006).
55. Seidel, P. et al. Dimethylfumarate inhibits NF-{kappa}B function at multiple levels to limit airway smooth muscle cell cytokine secretion. Am J Physiol Lung Cell Mol Physiol 297, L326-339, doi: 10.1152/ajplung.90624.2008 (2009).
56. Ashrafian, H. et al. Fumarate is cardioprotective via activation of the Nrf2 antioxidant pathway. Cell Metab 15, 361-371, doi: 10.1016/j.cmet.2012.01.017 (2012).
57. Kang, H. J. et al. Dimethylfumarate suppresses adipogenic differentiation in 3T3-L1 preadipocytes through inhibition of STAT3 activity. PLoS One 8, e61411, doi: 10.1371/journal.pone.0061411 (2013).
58. Bharti, A. C., Donato, N. & Aggarwal, B. B. Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells. J Immunol 171, 3863-3871 (2003).
59. Singh, S. & Aggarwal, B. B. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem 270, 24995-25000 (1995).
60. Balogun, E. et al. Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochem J 371, 887-895, doi: 10.1042/BJ20021619 (2003).
61. Pastore, A. & Piemonte, F. S-Glutathionylation signaling in cell biology: progress and prospects. Eur J Pharm Sci 46, 279-292, doi: 10.1016/j.ejps.2012.03.010 (2012).
62. Saengsai, J., Kongtunjanphuk, S., Yoswatthana, N., Kummalue, T. & Jiratchariyakul, W. Antibacterial and Antiproliferative Activities of Plumericin, an Iridoid Isolated from Momordica charantia Vine. Evid Based Complement Alternat Med 2015, 823178, doi: 10.1155/2015/823178 (2015).
63. Bauer, R. A. Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies. Drug Discov Today, doi: 10.1016/j.drudis.2015.05.005 (2015).
64. Zimmermann, K. et al. Activated AMPK boosts the Nrf2/HO-1 signaling axis-A role for the unfolded protein response. Free Radic Biol Med, doi: 10.1016/j.freeradbiomed.2015.03.030 (2015).
65. Griffith, O. W. Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal Biochem 106, 207-212 (1980).
66. Gerhauser, C. et al. Cancer chemopreventive potential of sulforamate, a novel analogue of sulforaphane that induces phase 2 drug-metabolizing enzymes. Cancer Res 57, 272-278 (1997).
67. Rahman, I., Kode, A. & Biswas, S. K. Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method. Nat Protoc 1, 3159-3165, doi: 10.1038/nprot.2006.378 (2006).